Strong Analytical Validation Data Further Supports Use of DCISionRT® to Guide Shared Decision-Making for DCIS Therapeutic Management
/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that...